active
ACTIVE SINCE: 2015
Back to Collaborations

Fosravuconazole treatment in eumycetoma

Fosravuconazole treatment in eumycetoma: corroborating study outcomes, preparing for access
SDGS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
MEMBER COMPANIES:
PARTNERING WITH:
SEE ALL PARTNER ORGANIZATIONS
Global NGOs 1
Objectives
  • Fosravuconazole treatment in eumycetoma: corroborating study outcomes, preparing for access

Eisai is collaborating with the DNDi for a new treatment for eumycetoma, a fungal form of mycetoma with a particularly high unmet medical need, and one of the world’s most neglected diseases. Eisai is mainly responsible for non-clinical studies and the provision of the investigational drug. A Phase IIb/III clinical study was conducted in Sudan by DNDi and the Mycetoma Research Center of the University of Khartoum, Sudan. Currently, preparation for regulatory filing to the regulatory authorities (National Medicines and Poisons Board) in Sudan is underway.

Results and milestones

There was no consensus on treatment for eumycetoma as no drugs have been studied in an RCT, except for fosravuconazole and itraconazole in the completed RCT. Fosravuconazole is expected to be a significant improvement considering the important medical needs of alternative therapies for mycetoma and advantages of fosravuconazole such as its once weekly administration, its favorable safety profile and it can be taken without food or drink, in addition to the favorable results shown by the completed RCT.

 

 

Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Men
  • Women
  • People with low incomes
Partner organizations
Global NGOs

Drugs for Neglected Diseases initiative (DNDi)

Geographic Reach

Global Commitment

Disease Area

Infectious and Parasitic Disease

  • Neglected Tropical Diseases (NTDs)
    • Mycetoma, chromoblastomycosis and other deep mycoses
of